A possible involvement of 3-monoglucuronyl-glycyrrhetinic acid, a metabolite of glycyrrhizin (GL), in GL-induced pseudoaldosteronism

Life Sciences

Volumn 80, Issue 17, 2007, Pages 1545-1552

  Ohtake, Nobuhiro ^a   Kido, Akiko ^a   Kubota, Kunitsugu ^a   Tsuchiya, Naoko ^a   Morita, Toshimi ^a   Kase, Yoshio ^a   Takeda, Shuichi ^a  

^a TSUMURA AND CO   (Japan)

Author keywords

3 monoglucuronyl glycyrrhetinic acid (3MGA); Glycyrrhizin (GL); Plasma potassium level (PPL); Pseudoaldosteronism; Toxicokinetics

Indexed keywords

3 GLUCURONYLGLYCYRRHETINIC ACID; ALCOHOL; FUROSEMIDE; GLYCYRRHETINIC ACID; GLYCYRRHETINIC ACID DERIVATIVE; GLYCYRRHIZIC ACID; MACROGOL; POTASSIUM; SWEETENING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STRUCTURE; GLYCYRRHIZA; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERALDOSTERONISM; HYPOKALEMIA; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; POTASSIUM BLOOD LEVEL; PSEUDOALDOSTERONISM; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY; TOXICOKINETICS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FUROSEMIDE; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; GUINEA PIGS; HYPERALDOSTERONISM; HYPOKALEMIA; INJECTIONS, INTRAVENOUS; MALE; POTASSIUM; SWEETENING AGENTS;

GLYCYRRHIZA;

EID: 33947188090     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.01.033     Document Type: Article

References (30)

1. Akao T. Distribution of enzymes involved in the metabolism of glycyrrhizin in various organs of rat. Biological and Pharmaceutical Bulletin 21 10 (1998) 1036-1044
2. Akao T., Hattori M., Kanaoka M., Yamamoto K., Namba T., and Kobashi K. Hydrolysis of glycyrrhizin to 18 beta-glycyrrhetyl monoglucuronide by lysosomal beta-d-glucuronidase of animal livers. Biochemical Pharmacology 41 6-7 (1991) 1025-1029
3. Bujalska I., Shimojo M., Howie A., and Stewart P.M. Human 11 beta-hydroxysteroid dehydrogenase: studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue. Steroids 62 1 (1997) 77-82
4. Conn J.W., Rovner D.R., and Cohen E.L. Licorice-induced pseudoaldosteronism. Hypertension, hypokalemia, aldosteronopenia, and suppressed plasma renin activity. The journal of the American Medical Association 205 7 (1968) 492-496
5. Cotter G., Weissgarten J., Metzkor E., Moshkovitz Y., Litinski I., Tavori U., Perry C., Zaidenstein R., and Golik A. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clinical Pharmacology and Therapeutics 62 2 (1997) 187-193
6. Ferrari P., Bianchetti M.G., Sansonnens A., and Frey F.J. Modulation of renal calcium handling by 11 beta-hydroxysteroid dehydrogenase type 2. Journal of the American Society of Nephrology 13 10 (2002) 2540-2546
7. Gerlag P.G., and van Meijel J.J. High-dose furosemide in the treatment of refractory congestive heart failure. Archives of Internal Medicine 148 2 (1988) 286-291
8. Heilmann P., Heide J., Hundertmark S., and Schoneshofer M. Administration of glycyrrhetinic acid: significant correlation between serum levels and the cortisol/cortisone-ratio in serum and urine. Experimental and Clinical Endocrinology and Diabetes 107 6 (1999) 370-378
9. Kageyama Y., Suzuki H., and Saruta T. Renin-dependency of glycyrrhizin-induced pseudoaldosteronism. Endocrinologia Japonica 38 1 (1991) 103-108
10. Kanaoka M., Yano S., Kato H., and Nakada T. Synthesis and separation of 18 beta-glycyrrhetyl monoglucuronide from serum of a patient with glycyrrhizin-induced pseudo-aldosteronism. Chemical and Pharmaceutical Bulletin 34 12 (1986) 4978-4983
11. Kanda H., Sakurai M., and Arima K. Licorice of 'shakuyaku kanzou tou' induced pseudoaldosteronism. Hinyokika Kiyo 50 3 (2004) 215-217
12. Kato H., Kanaoka M., Yano S., and Kobayashi M. 3-Monoglucuronyl-glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism. The Journal of Clinical Endocrinology and Metabolism 80 6 (1995) 1929-1933
13. Kullak-Ublick G.A., Baretton G.B., Oswald M., Renner E.L., Paumgartner G., and Beuers U. Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. Hepatology Research 23 1 (2002) 78-82
14. Messner M., and Brissot P. Traditional management of liver disorders. Drugs 40 Suppl 3 (1990) 45-57
15. Miyake K., Tango T., Ota Y., Mitamura K., Yoshiba M., Kako M., Hayashi S., Ikeda Y., Hayashida N., Iwabuchi S., Sato Y., Tomi T., Funaki N., Hashimoto N., Umeda T., Miyazaki J., Tanaka K., Endo Y., and Suzuki H. Efficacy of stronger Neo-Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis. Journal of Gastroenterology and Hepatology 17 11 (2002) 1198-1204
16. Monder C., Stewart P.M., Lakshmi V., Valentino R., Burt D., and Edwards C.R. Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology 125 2 (1989) 1046-1053
17. Moon A., and Kim S.H. Effect of Glycyrrhiza glabra roots and glycyrrhizin on the glucuronidation in rats. Planta Medica 63 2 (1997) 115-119
18. Nakatsumi Y., Abe T., Nomura G., Fujimura M., and Matsuda T. Bronchial asthma due to stronger Neo-Minophagen C. Nihon Kokyuki Gakkai Zasshi - Journal of the Japanese Respiratory Society 36 7 (1998) 644-646
19. Nishioka Y., Kyotani S., Miyamura M., and Kusunose M. Influence of time of administration of a Shosaiko-to extract granule on blood concentration of its active constituents. Chemical and Pharmaceutical Bulletin 40 5 (1992) 1335-1337
20. Okita K., Sakaida I., and Hino K. Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 62 Suppl 1 (2002) 24-28
21. Raggi M.A., Bugamelli F., Nobile L., Schiavone P., and Cantelli-Forti G. HPLC determination of glycyrrhizin and glycyrrhetic acid in biological fluids, after licorice extract administration to humans and rats. Bollettino Chimico Farmaceutico 133 11 (1994) 704-708
22. Ros J.E., Libbrecht L., Geuken M., Jansen P.L., and Roskams T.A. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. The Journal of Pathology 200 5 (2003) 553-560
23. Serra A., Uehlinger D.E., Ferrari P., Dick B., Frey B.M., Frey F.J., and Vogt B. Glycyrrhetinic acid decreases plasma potassium concentrations in patients with anuria. Journal of the American Society of Nephrology 13 1 (2002) 191-196
24. Shimamura H., Suzuki H., Tagaya O., Horie T., and Sugiyama Y. Biliary excretion of glycyrrhizin in rats: kinetic basis for multiplicity in bile canalicular transport of organic anions. Pharmaceutical Research 13 12 (1996) 1833-1837
25. Shimizu I. Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. Journal of Gastroenterology and Hepatology 15 (2000) D84-D90 (Suppl)
26. Shintani S., Murase H., Tsukagoshi H., and Shiigai T. Glycyrrhizin (licorice)-induced hypokalemic myopathy. Report of 2 cases and review of the literature. European Neurology 32 1 (1992) 44-51
27. Sigurjonsdottir H.A., Franzson L., Manhem K., Ragnarsson J., Sigurdsson G., and Wallerstedt S. Liquorice-induced rise in blood pressure: a linear dose-response relationship. Journal of Human Hypertension 15 8 (2001) 549-552
28. van Rossum T.G., Vulto A.G., de Man R.A., Brouwer J.T., and Schalm S.W. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Alimentary Pharmacology and Therapeutics 12 3 (1998) 199-205
29. van Rossum T.G., de Jong F.H., Hop W.C., Boomsma F., and Schalm S.W. 'Pseudo-aldosteronism' induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients. Journal of Gastroenterology and Hepatology 16 7 (2001) 789-795
30. Walker B.R., and Best R. Clinical investigation of 11 beta-hydroxysteroid dehydrogenase. Endocrine Research 21 1-2 (1995) 379-387